β¨ Medicines Consent Notices
NEW ZEALAND GAZETTE
No. 114
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Ketoprofen 100 mg, 200 mg | capsules | Elan Pharma Limited, Athlone, Ireland | Kapren SR |
| Theophylline (anhydrous) 250 mg, 375 mg | slow release capsule | Byk Nederland BV, Swanenberg, The Netherlands | Euphylong |
| This product is not substitutable with other Theophylline medicines | |||
| Methyl salicylate 20% w/w, Menthol 0.75% w/w, Camphor 1.0% w/w, Eucalyptus Oil 0.5% w/w | topical cream | Milpharma Pty Limited, Brookvale, New South Wales, Australia | Dencorub |
| Indomethacin 1% w/w | topical solution | Luitpold-Pharma GmbH, Munchen, Germany | Elmetacin |
| Pine Tar 2.3% | topical solution | Hamilton Laboratories, Adelaide, South Australia | Dermatar |
| 4-hydroxyandrostenedione 250 mg | powder for reconstitution for injection | Ciba-Geigy Limited, Basle, Switzerland | Lentaron |
| Haemophilus influenzae type b conjugate vaccine containing H.influenzae type b polysaccharide 15.0 mcg and N.meningitidis group B (strain B11) outer membrane protein complex 225.0 mcg per dose. | lyophilised powder with aluminium hydroxide diluent for injection | Merck & Co. Inc., West Point, Pennsylvania, United States of America | Pedvax HIB |
| Estradiol 50 mcg norethisterone 0.25 mg | transdermal therapeutic system (patches) | Ciba-Geigy Limited, Basle, Switzerland | Estragest TTS |
| Estradiol 50 mcg estradiol 50 mcg/0.25 mg norethisterone | transdermal therapeutic system (patches) | Ciba-Geigy Limited, Basle, Switzerland | Estracomb TTS |
Dated this 16th day of July 1992.
C. LOVEACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 5th day of June 1991.
go6594
Consent to the Distribution of Changed Medicines
Pursuant to section 24 (5) of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines set out in the Schedule hereto:
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Nifedipine 30 mg, 60 mg, 90 mg | controlled release tablet | Pfizer Pharmaceutical Inc., Barceloneta, Puerto Rico and Alza Corporation, Vacaville, California, United States of America | Adalat Oros |
| Etodolac 400 mg, 600 mg | slow release tablets | Wyeth S.p.a., Aprilia (Latina), Italy | Lodine |
| Etodolac 200 mg, 300 mg | tablets | John Wyeth & Brother Limited, Taplow, Maidenhead, Berkshire, United Kingdom | Lodine |
| Etodolac 300 mg | capsules | John Wyeth & Brother Limited, Taplow, Maidenhead, Berkshire, United Kingdom | Lodine |
| Isradipine 100 ug/ml | solution for intravenous administration | Sandoz Pharma Limited, Basle, Switzerland | Dynacirc IV |
Dated this 16th day of July 1992.
C. LOVEACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 5th day of July 1992.
go6595
Next Page →
PDF embedding disabled (Crown copyright)
View this page online at:
VUW Te Waharoa —
NZ Gazette 1992, No 114
NZLII —
NZ Gazette 1992, No 114
β¨ LLM interpretation of page content
π₯
Consent to Distribution of New Medicines
(continued from previous page)
π₯ Health & Social Welfare16 July 1992
Medicines, Distribution, Consent, Schedule
- C. Loveace, Director-General of Health
π₯ Consent to the Distribution of Changed Medicines
π₯ Health & Social Welfare16 July 1992
Medicines, Distribution, Consent, Schedule, Changes
- C. Loveace, Director-General of Health